Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Report 2026

Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview

• Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical market size has reached to $6.53 billion in 2025 • Expected to grow to $9.62 billion in 2030 at a compound annual growth rate (CAGR) of 8.1% • Growth Driver: The Prevalence Of Cancer Is Fueling Market Growth Due To Increasing Demand For Advanced Diagnostic Imaging And Radiopharmaceuticals • Market Trend: Innovative Cardiac Imaging Technique Enhances Patient Evaluation For Heart Disease • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market?

SPECT or PET radiopharmaceuticals are radioactive compounds administered to patients that emit detectable signals, enabling imaging of organ function and physiological processes using SPECT or PET scanners. These agents emit signals detected by SPECT or PET scanners, enabling detailed analysis of biological activity for diagnosis. The main types of radiopharmaceuticals of single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical include single photon emission computed tomography and positron emission tomography. Single photon emission computed tomography refers to imaging agents that emit gamma rays for diagnostic imaging of organ function and structure. These radiopharmaceuticals utilize radioisotope types such as technetium-99m, fluorine-18, iodine-123, and gallium-68, and are administered through injectable, inhalation, and oral routes. The various applications involved are oncology, cardiology, neurology, and other application areas, and they are used by several end users such as hospitals, diagnostic imaging centers, research institutions, and other end users.

What Is The Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Growth Forecast?

The single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market size is expected to see strong growth in the next few years.It will grow to $9.62 billion by 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing demand for personalized diagnostic solutions, growth in theranostics applications, rising investment in nuclear medicine research, advancements in radioisotope production technologies, expanding use of pet imaging in clinical practice.Major trends in the forecast period include increasing adoption of targeted radiopharmaceuticals for disease-specific imaging, growing demand for hybrid imaging techniques combining spect and pet modalities, rising use of short half-life isotopes for improved safety and imaging precision, expansion of radiopharmaceutical applications in oncology and neurology, increasing focus on early disease detection and functional imaging.

Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Segmentation

1) By Type Of Radiopharmaceuticals: Single Photon Emission Computed Tomography, Positron Emission Tomography 2) By Radioisotope Type: Technetium-99m, Fluorine-18, Iodine-123, Gallium-68 3) By Route Of Administration: Injectable, Inhalation, Oral 4) By Application Areas: Oncology, Cardiology, Neurology, Other Application Areas 5) By End User: Hospitals, Diagnostic Imaging Centers, Research Institutions, Other End Users Subsegments: 1) By Single Photon Emission Computed Tomography: Cardiac Imaging Agents, Bone Imaging Agents, Renal Imaging Agents, Pulmonary Imaging Agents, Thyroid Imaging Agents 2) By Positron Emission Tomography: Oncology Imaging Agents, Neurology Imaging Agents, Cardiology Imaging Agents, Infection And Inflammation Imaging Agents, Metabolic Imaging Agents

What Is The Driver Of The Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market?

The rising prevalence of cancer is expected to propel the growth of the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical industry going forward.Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body, which can form tumors and interfere with normal bodily functions.The prevalence of cancer is growing due to the aging population, as older individuals have a higher likelihood of accumulating genetic mutations that can trigger uncontrolled cell growth.SPECT and PET radiopharmaceuticals enable highly sensitive and precise imaging of tumors, facilitating early cancer detection, accurate staging, treatment monitoring, and guidance for personalized therapy decisions.For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022.Therefore, the rising prevalence of cancer is driving the growth of the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical industry.

Key Players In The Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

Major companies operating in the single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies Inc., Bracco Imaging S. p. A., Lantheus Holdings Inc., Jubilant Pharmova Limited, Curium Pharma, Sofie Biosciences Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler SE, Advanced Accelerator Applications S. A., Nordion Inc., NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, Eczacıbaşı-Monrol Nuclear Products, Radioisotope Centre POLATOM, IBA Radiopharma Solutions, Dongcheng, Pars Isotope Company

Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Trends and Insights

Major companies operating in the positron emission tomography (PET) radiopharmaceutical market are focusing on developing innovative products such a, cardiac positron emission tomography (PET) tracers to improve diagnostic accuracy and accessibility in coronary artery disease imaging. Cardiac positron emission tomography (PET) tracers are radioactive compounds used in PET imaging to visualize blood flow and detect areas of reduced perfusion in the heart, helping clinicians accurately diagnose coronary artery disease and assess myocardial ischemia and infarction in a noninvasive and highly sensitive manner. For instance, in September 2024, GE HealthCare, a U. S. -based medical technology and pharmaceutical diagnostics company, received U. S. Food and Drug Administration (FDA) approval for Flyrcado (flurpiridaz F 18), a cardiac PET (positron emission tomography) tracer for myocardial perfusion imaging (MPI) in patients with known or suspected coronary artery disease. Flyrcado is a ready-to-use unit dose radiotracer with a long half-life of 109 minutes, enabling high-resolution PET imaging, exercise stress testing, and rescans in the same session, improving diagnostic accuracy compared to traditional SPECT MPI agents. This approval expands access to advanced cardiac PET imaging, particularly benefiting difficult-to-image patients such as women and those with high body mass index (BMI).

What Are Latest Mergers And Acquisitions In The Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market?

In January 2026, SHINE Technologies LLC, a US‑based healthcare technology and nuclear medicine production company, acquired Lantheus Holdings’ SPECT business for an undisclosed amount. With this acquisition, SHINE aims to expand its capabilities and market presence in nuclear medicine by taking over established SPECT diagnostic products and manufacturing operations while ensuring continuity and growth of that business. Lantheus Holdings Inc. is a US‑based healthcare technology company that specialized in providing SPECT radiopharmaceutical diagnostic agents and related manufacturing operations used in single photon emission computed tomography imaging.

Regional Insights

North America was the largest region in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market?

The single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market consists of sales of products such as diagnostic radiotracers, therapeutic radiopharmaceuticals, and radionuclide compounds such as technetium-99m, fluorine-18, and iodine-131. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

What is the Market Assessment and Strategic Outlook for the Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Industry?

The single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

What is the Market Assessment and Strategic Outlook for the Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Report 2026?

The single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market research report is one of a series of new reports from The Business Research Company that provides single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market statistics, including single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical industry global market size, regional shares, competitors with a single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market share, detailed single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market segments, market trends and opportunities, and any further data you may need to thrive in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical industry. This single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.